Skip to main content
OpenTrials
Completed

NCT Number: NCT06008678

Study of the Resvent RXiBreeze™ PAP System to Treat Obstructive Sleep Apnea

The goal of this clinical trial is to test the automatic positive airway pressure (APAP) function of the RXiBreeze PAP System in adult subjects with obstructive sleep apnea (OSA). The main questions the study aims to answer are:

1. Is apnea-hypopnea index (AHI) detection using the RXiBreeze PAP System equivalent to apnea-hypopnea index (AHI) detection using PSG? 2. What is the responder rate using the RXiBreeze PAP System?

Participants will use the APAP function of the RXiBreeze PAP System while undergoing polysomnography (PSG) for two separate nights in a sleep center. During each visit, participants will also complete two patient reported outcome questionnaires:

* Epworth Sleepiness Score (ESS); and * Functional Outcomes of Sleep Questionnaire (FOSQ) short form.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Obstructive Sleep Apnea Apnea Dyssomnias Nervous System Diseases Respiration Disorders Respiratory Tract Diseases Sleep Apnea Syndromes Sleep Apnea, Obstructive Sleep Disorders, Intrinsic Sleep Wake Disorders

Age range

22 year and older

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

Peninsula Sleep Center, Burlingame, California, United States

Loading trial locations.

About this study

This is a prospective, multicenter, single-arm trial designed to evaluate the safety and effectiveness of the RXiBreeze PAP System to treat obstructive sleep apnea and detect breathing events. Eligible subjects who meet all inclusion criteria and none of the exclusion criteria will be consented for study participation. The study will enroll up to 68 subjects. Baseline PSG will be obtained. Subjects will return to the sleep lab and use the RXiBreeze PAP System while undergoing a PSG. The data from both the RXiBreeze PAP System and PSG from both nights will be sent to an independent core lab for blinded AHI scoring. Data will be evaluated in accordance with current American Academy of Sleep Medicine (AASM) scoring guidelines. In addition to the device/PSG data scoring, subjects will complete the Epworth Sleepiness Score (ESS) and the Functional Outcomes of Sleep Questionnaire (FOSQ) short form (10 questions) and be assessed for device- and/or therapy-related adverse events (AEs) at the end of each visit.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Subject is ≥ 22 years old
  • Subject has been diagnosed with OSA (as scored per AASM scoring guidelines) and has an AHI ≥ 10, based on the results of a sleep study conducted at an accredited sleep lab, within 30 days prior to enrollment
  • Subject weighs >30 kg
  • Subject has been prescribed the use of an Auto CPAP system
  • Subject agrees to fulfill all study-required tests, sleep lab session attendance, and assessments
  • Subject agrees to use the RXiBreeze PAP System as prescribed
  • Subject is willing and able to provide informed consent

Exclusion criteria

  • Subject has been diagnosed with a sleep disorder other than OSA
  • Subject's Central Apnea Index from the baseline PSG is > 20% of AHI
  • Subject has been diagnosed with severe (stage 3) coronary artery disease
  • Subject has been diagnosed with bullous lung disease
  • subject has been diagnosed with hypotension
  • subject has been diagnosed with bypassed upper airway pneumothorax
  • Subject is pregnant, breastfeeding, or planning on becoming pregnant during trial participation
  • Subject, in the opinion of the investigator, is not suitable for trial participation

Treatment and study plan

RXiBreeze PAP System, Model RXiBreeze 20A

Device

The RXiBreeze PAP System is a prescription-only positive airway pressure (PAP) ventilator used to treat obstructive sleep apnea (OSA). It is a microprocessor-controlled device that provides mechanical ventilation to a subject.

Primary outcomes

  1. AHI Event Detection

    Time frame: Night 1

    Apnea-Hypopnea Index (AHI) as measured by the test device (RXiBreeze PAP System) will be compared to the AHI as measured by polysomnography (PSG) to determine equivalence at night 1. Equivalence will be considered if the mean difference in detected AHI is greater than the lower equivalence limit (EL) of -5 and less than the upper equivalence limit (EU) of 5.

  2. Responder Rate

    Time frame: Night 1

    RXiBreeze PAP System Night 1 responder rate as compared to a performance goal of 50. Responder rate is based on Sher's Criteria, which are defined as having both a ≥ 50% reduction in AHI and a final AHI of < 20 events per hour.

Secondary outcomes

  1. Night 7 responder rate

    Time frame: Night 7

    . Responder rate is based on Sher's Criteria, which are defined as having both a ≥ 50% reduction in AHI and a final AHI of < 20 events per hour.

  2. Night 1 responder rate by baseline disease severity

    Time frame: Night 1

    Responder rate presented by disease severity in accordance with AASM scoring guidelines. Responder rate is based on Sher's Criteria, which are defined as having both a ≥ 50% reduction in AHI and a final AHI of < 20 events per hour.

  3. Night 7 RXiBreeze PAP System compliance rate

    Time frame: Night 7

    Compliance rate is measure of subject use of the RXiBreeze PAP System presented by descriptive statistics.

  4. Nights 1 and 7 Oxygen Desaturation Index (ODI)

    Time frame: Nights 1 and 7

    ODI is average number of desaturation episodes per hour. ODI will be presented by descriptive statistics.

  5. Nights 1 and 7 percentage of time oxygen saturation is < 90% (T90)

    Time frame: Nights 1 and 7

    Oxygen saturation is a measure of the amount of oxygen that is circulating in the blood. T90 oxygen saturation will be presented by descriptive statistics.

  6. Event Detection Validation - Obstructive Apnea Index (OAI) on Night 1 and Night 7

    Time frame: Nights 1 and 7

    Obstructive Apnea Index (OAI) as measured by the test device (RXiBreeze PAP System) will be compared to the OAI as measured by polysomnography (PSG) to validate accuracy of the test device at nights 1 and 7. Frequency and percentages will be presented.

  7. Event Detection Validation: Hypopnea Index (HI) on Night 1 and Night 7

    Time frame: Nights 1 and 7

    Event Detection Validation: Hypopnea Index (HI) as measured by the test device (RXiBreeze PAP System) will be compared to the HI as measured by polysomnography (PSG) to validate accuracy of the test device at nights 1 and 7. Frequency and percentages will be presented.

  8. Event Detection Validation: Central Apnea Index (CAI) on Night 1 and Night 7

    Time frame: Nights 1 and 7

    Event Detection Validation: Central Apnea Index (CAI) as measured by the test device (RXiBreeze PAP System) will be compared to the CAI as measured by polysomnography (PSG) to validate accuracy of the test device at nights 1 and 7. Frequency and percentages will be presented.

  9. Event Detection Validation: Apnea Index (AI) on Night 1 and Night 7

    Time frame: Nights 1 and 7

    Event Detection Validation: Apnea Index (AI) as measured by the test device (RXiBreeze PAP System) will be compared to the AI as measured by polysomnography (PSG) to validate accuracy of the test device at nights 1 and 7. Frequency and percentages will be presented.

  10. Epworth Sleepiness Scale (ESS) on Night 1 and Night 7

    Time frame: Nights 1 and 7

    Epworth Sleepiness Scale (ESS) is a validated patient reported outcome (PRO) questionnaire consisting of 8 questions related to daytime sleepiness. The ESS results in a score from 0 to 24 (0 - 10 reflect normal levels of daytime sleepiness, scores over 10 reflect excessive daytime sleepiness (EDS), scores of 16 or more suggest a high level of EDS. The ESS will be self-administered by subjects at the Night 1 and Night 7 visits. Results will be presented by frequency and percentages.

  11. Functional Outcomes of Sleep Questionnaire short form (FOSQ-10) on Night 1 and Night 7

    Time frame: Nights 1 and 7

    Functional Outcomes of Sleep Questionnaire (FOSQ) short form is a validated patient reported outcome (PRO) questionnaire consisting of 10 questions related to the impact of sleepiness on the ability to conduct daily activities. The FOSQ-10 questions are rates on a scale of 1 to 4 (1=extreme difficulty and 4=no difficulty). A total score and 5 subscale scores (vigilance, general productivity, social outcome, intimacy, and activity level) are calculated. Subscale scores range from 1 (maximum difficulty) to 4 (no difficulty).

Other outcomes

  1. Safety Endpoint: Device- and/or therapy-related adverse events (AEs)

    Time frame: Night 1 through completion of Night 7

    Device- and/or therapy-related adverse events (AEs) will be collected from the Night 1 visit through completion of the Night 7 visit. AEs will be coded using the standardized Medical Dictionary for Regulatory Activities (MedDRA). AEs will be reported by subject and event.

Sponsors and collaborators

Lead sponsor

Resvent Holding USA LTD

Industry

Collaborators

  • Avania
  • Resvent Medical Technology Co., Ltd.

Registry information

Official study title

A Multicenter, Single-Arm, Safety and Efficacy Study of the Resvent RXiBreeze™ PAP System to Treat Obstructive Sleep Apnea

Important dates

Study start
2023
Primary completion
2023
Study completion
2023
First posted
Aug 23, 2023
Registry last updated
Dec 2, 2024

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.